Max Yates

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9085537/publications.pdf

Version: 2024-02-01

30 papers	1,432 citations	932766 10 h-index	22 g-index
30	30	30	2020
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical and biomechanical factors associated with falls and rheumatoid arthritis: baseline cohort with longitudinal nested case–control study. Rheumatology, 2022, 61, 679-687.	0.9	3
2	Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?. Current Rheumatology Reports, 2022, 24, 111-117.	2.1	1
3	Impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases in the UK: a mixed-methods study. BMJ Open, 2021, 11, e048772.	0.8	18
4	Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study. Rheumatology, 2020, 59, 319-323.	0.9	11
5	Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study. Annals of the Rheumatic Diseases, 2020, 79, 547-549.	0.5	O
6	Accessing health services for musculoskeletal diseases during early COVID-19 lockdown: Results from a UK population survey. Rheumatology Advances in Practice, 2020, 4, rkaa047.	0.3	2
7	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. Journal of Rheumatology, 2020, 47, 1379-1384.	1.0	10
8	O14 \hat{a} Pro-inflammatory diets are associated with increased C-reactive protein and subsequent rheumatoid arthritis in the European Investigation of Cancer: Norfolk Arthritis Register cohort. Rheumatology, 2019, 58, .	0.9	0
9	215â€fPredictors of resilience in severe rheumatoid arthritis: an analysis of data from the Norfolk Arthritis Register. Rheumatology, 2019, 58, .	0.9	O
10	217â€fResults of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica. Rheumatology, 2019, 58, .	0.9	0
11	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. Journal of Rheumatology, 2019, 46, 1360-1364.	1.0	5
12	FRIO657â€METABOLIC SYNDROME PRECEDES THE ONSET OF HIP AND KNEE PAIN AND THE RISK IS NOT MODIFIED BY DIET OR CHANGES IN BMI. , 2019, , .		0
13	Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study. Annals of the Rheumatic Diseases, 2019, 78, 704-705.	0.5	2
14	088â€fCardiovascular risk factors are associated with the onset of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective cohort: EPIC-Norfolk study. Rheumatology, 2018, 57, .	0.9	0
15	Conventional and biological immunosuppressants in vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 94-111.	1.4	9
16	The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology, 2017, 56, kew397.	0.9	16
17	ANCA-associated vasculitis. Clinical Medicine, 2017, 17, 60-64.	0.8	153
18	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	1.8	23

#	Article	IF	CITATIONS
19	Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. Clinical and Experimental Rheumatology, 2017, 35, 1-2.	0.4	11
20	Does the co-existence of acute anterior uveitis and chronic back pain prompt primary care physicians to consider a diagnosis of axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2016, 75, e18-e18.	0.5	1
21	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.5	940
22	The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskeletal Disorders, 2016, 17, 285.	0.8	41
23	Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis?: Table 1. Rheumatology, 2016, 55, 769-772.	0.9	2
24	Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial. Journal of Rheumatology, 2015, 42, 1177-1185.	1.0	44
25	ANCA-associated vasculitis – Should we change the standard of care?. Indian Journal of Rheumatology, 2015, 10, S54-S58.	0.2	O
26	Body Mass Index, Smoking, and Alcohol and Risks of Barrett's Esophagus and Esophageal Adenocarcinoma: A UK Prospective Cohort Study. Digestive Diseases and Sciences, 2014, 59, 1552-1559.	1.1	38
27	Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clinical Rheumatology, 2014, 33, 227-236.	1.0	51
28	Pyomyositis. Journal of Diabetes and Its Complications, 2011, 25, 346-348.	1.2	8
29	Acute and general medicine for the physician. Clinical Medicine, 2010, 10, 577-578.	0.8	O
30	Oncological Emergency Admissions to the Norfolk and Norwich University Hospital: An Audit of Current Arrangements and Patient Satisfaction. Clinical Oncology, 2009, 21, 226-233.	0.6	43